<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">endofocus</journal-id><journal-title-group><journal-title xml:lang="ru">FOCUS Эндокринология</journal-title><trans-title-group xml:lang="en"><trans-title>FOCUS. Endocrinology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2713-0177</issn><issn pub-type="epub">2713-0185</issn><publisher><publisher-name>ООО "Издательство "Перо"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.62751/2713-0177-2024-5-1-10</article-id><article-id custom-type="elpub" pub-id-type="custom">endofocus-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЙ СЛУЧАЙ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL CASE</subject></subj-group></article-categories><title-group><article-title>Синдром мнимого избытка  минералокортикоидов: клинический случай</article-title><trans-title-group xml:lang="en"><trans-title>Syndrome of imaginary excess of mineralocorticoids: a clinical case</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6876-3336</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нуралиева</surname><given-names>Н. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Nuralieva</surname><given-names>N. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Нуралиева Нурана Фейзуллаевна, научный сотрудник отделения терапии заболеваний щитовидной железы, надпочечников и   ожирения</p><p>117292, г.   Москва, ул. Дмитрия Ульянова, 11</p></bio><bio xml:lang="en"><p>Nurana H. Nuralieva , Researcher at the Department of Treatment of patients with ito-a prominent resident, adrenal glands and obesity</p><p>Moscow</p></bio><email xlink:type="simple">nnurana@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7285-6874</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лавренюк</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Lavrenyuk</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лавренюк Анастасия Андреевна , ординатор</p><p>117292, г.   Москва, ул. Дмитрия Ульянова, 11</p></bio><bio xml:lang="en"><p>Anastasia  A.  Lavrenyuk, resident</p><p>Moscow</p></bio><email xlink:type="simple">lavanasta.box@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Аджиасанова</surname><given-names>М. Ж.</given-names></name><name name-style="western" xml:lang="en"><surname>Adjiasanova</surname><given-names>M. Zh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Аджиасанова Мавиле Жемилевна, ординатор</p><p>117292, г.   Москва, ул. Дмитрия Ульянова, 11</p></bio><bio xml:lang="en"><p>Mavile Zh. Adjiasanova , resident</p><p>Moscow</p></bio><email xlink:type="simple">adzhiasanova99@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8771-8300</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Юкина</surname><given-names>М. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Yukina</surname><given-names>M. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Юкина Марина Юрьевна, к.  м.  н., заведующая отделением терапии заболеваний щитовидной железы, надпочечников и  ожирения</p><p>117292, г.   Москва, ул. Дмитрия Ульянова, 11</p></bio><bio xml:lang="en"><p>Marina Yu. Yukina, Can. Sci. (Med.), Head of the Department of Therapy of Thyroid, Adrenal and Obesity Diseases</p><p>Moscow</p></bio><email xlink:type="simple">kuronova@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4915-1267</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чугунов</surname><given-names>И. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Chugunov</surname><given-names>I. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Чугунов Игорь Сергеевич, к.  м.  н., заведующий детским отделением опухолей эндокринной системы</p><p>117292, г.   Москва, ул. Дмитрия Ульянова, 11</p></bio><bio xml:lang="en"><p>Igor  S.  Chugunov, Can. Sci. (Med.), Head of the Pediatric Department of Tumors of the Endocrine System</p><p>Moscow</p></bio><email xlink:type="simple">chugunov.igor@endocrincentr.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6388-1544</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Платонова</surname><given-names>Н. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Platonova</surname><given-names>N. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Платонова Надежда Михайловна, д. м.  н., заведующая отделом терапевтической эндокринологии</p><p>117292, г.   Москва, ул. Дмитрия Ульянова, 11</p></bio><bio xml:lang="en"><p>Nadezhda M. Platonova, Doc. Sci. (Med.), Head of the Department of Therapeutic Endocrinology, Endocrinology Research Centre</p><p>Moscow</p></bio><email xlink:type="simple">doc-platonova@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8520-8702</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Трошина</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Troshina</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Трошина Екатерина Анатольевна, д.  м.  н., профессор, член-корреспондент РАН, директор Института клинической эндокринологии</p><p>117292, г.   Москва, ул. Дмитрия Ульянова, 11</p></bio><bio xml:lang="en"><p>Ekaterina  A.   Troshina , Doc. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences, Director of the Institute of Clinical Endocrinology</p><p>Moscow</p></bio><email xlink:type="simple">troshina@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Государственный научный центр Российской Федерации Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр эндокринологии» Министерства здравоохранения Российской Федерации</institution></aff><aff xml:lang="en"><institution>Endocrinology Research Centre</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>07</day><month>05</month><year>2024</year></pub-date><volume>5</volume><issue>1</issue><fpage>74</fpage><lpage>80</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Нуралиева Н.Ф., Лавренюк А.А., Аджиасанова М.Ж., Юкина М.Ю., Чугунов И.С., Платонова Н.М., Трошина Е.А., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Нуралиева Н.Ф., Лавренюк А.А., Аджиасанова М.Ж., Юкина М.Ю., Чугунов И.С., Платонова Н.М., Трошина Е.А.</copyright-holder><copyright-holder xml:lang="en">Nuralieva N.F., Lavrenyuk A.A., Adjiasanova M.Z., Yukina M.Y., Chugunov I.S., Platonova N.M., Troshina E.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://endofocus.elpub.ru/jour/article/view/5">https://endofocus.elpub.ru/jour/article/view/5</self-uri><abstract><p>Синдром мнимого избытка минералокортикоидов (МИМ) –    редкое генетическое заболевание, характеризующееся ювенильной гипертензией, гипокалиемией, супрессией ренина и альдостерона. Синдром МИМ обусловлен мутацией в гене HSD11B2, который кодирует 11β-гидроксистероиддегидрогеназу  2 типа, превращающую кортизол в кортизон.</p><p>Целью статьи является описание клинического случая генетически подтвержденного (мутация с. 911А&gt;G гена HSD11B2) синдрома МИМ. Заболевание манифестировало в первые годы жизни; пациенту назначались антагонисты минералокортикоидных  рецепторов, препараты калия, калийсберегающие диуретики, другая антигипертензивная терапия. В связи с отсутствием стойкой нормотонии и нормокалиемии с 12 лет назначен дексаметазон. Вследствие неконтролируемой артериальной гипертензии и гипокалиемии развились осложнения (медуллярный нефрокальциноз, ремоделирование миокарда), а длительный прием дексаметазона привел к замедлению  темпов полового созревания и снижению минеральной плотности костной ткани.</p></abstract><trans-abstract xml:lang="en"><p>The syndrome of apparent  mineralocorticoid excess (AME) is a rare genetic disease characterized by  juvenile hypertension, hypokalemia, suppression of renin and aldosterone. AME syndrome is caused by a mutation in the HSD11B2 gene, which encodes 11ß-hydroxysteroid dehydrogenase type 2, that converts cortisol into cortisone.</p><p>The  purpose of the article is to describe a clinical case  of genetically confirmed (mutation C.911A&gt;G of the HSD11B2 gene) AME  syndrome. The disease manifested in the first years of life; the patient was prescribed mineralocorticoid receptor antagonists, potassium preparations, potassium-sparing diuretics, and other antihypertensive therapy. Due to the absence of normotonia and normokalemia, dexamethasone has been prescribed since the age  of 12. Due to uncontrolled arterial hypertension and hypokalemia, complications  developed (medullary nephrocalcinosis, myocardial remodeling), and prolonged dexamethasone intake led  to a slowdown in puberty and a decrease in bone  mineral density.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>мнимый избыток минералокортикоидов</kwd><kwd>артериальная гипертензия</kwd><kwd>гипокалиемия</kwd><kwd>антагонисты минералокортикоидных рецепторов</kwd><kwd>дексаметазон</kwd></kwd-group><kwd-group xml:lang="en"><kwd>apparent mineralocorticoid excess</kwd><kwd>hypertension</kwd><kwd>hypokalemia</kwd><kwd>mineralocorticoid receptor antagonists</kwd><kwd>dexamethasone</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=320.</mixed-citation><mixed-citation xml:lang="en">https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=320.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Lu Y. [и др.]. Apparent mineralocorticoid excess: comprehensive overview of molecular genetics // Journal of Translational Medicine. 2022. Т. 20. № 1.</mixed-citation><mixed-citation xml:lang="en">Lu Y. [и др.]. Apparent mineralocorticoid excess: comprehensive overview of molecular genetics // Journal of Translational Medicine. 2022. Т. 20. № 1.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Yau M. [и др.]. Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11β-hydroxysteroid dehydrogenase type 2 deficiency // Proceedings of the National Academy of Sciences of the United States of America. 2017. № 52 (114). C. E11248–E11256.</mixed-citation><mixed-citation xml:lang="en">Yau M. [и др.]. Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11β-hydroxysteroid dehydrogenase type 2 deficiency // Proceedings of the National Academy of Sciences of the United States of America. 2017. № 52 (114). C. E11248–E11256.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Harbi T., Al-Shaikh A. Apparent mineralocorticoid excess syndrome: Report of one family with three affected children // Journal of Pediatric Endocrinology and Metabolism. 2012. № 11–12 (25). C. 1083–1088.</mixed-citation><mixed-citation xml:lang="en">Al-Harbi T., Al-Shaikh A. Apparent mineralocorticoid excess syndrome: Report of one family with three affected children // Journal of Pediatric Endocrinology and Metabolism. 2012. № 11–12 (25). C. 1083–1088.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Funder J. W. Apparent mineralocorticoid excess // Journal of Steroid Biochemistry and Molecular Biology. 2017. Т. 165. C. 151–153.</mixed-citation><mixed-citation xml:lang="en">Funder J. W. Apparent mineralocorticoid excess // Journal of Steroid Biochemistry and Molecular Biology. 2017. Т. 165. C. 151–153.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Palermo M., Quinkler M., Stewart P. M. revisão Apparent Mineralocorticoid Excess Syndrome: An Overview. 2004.</mixed-citation><mixed-citation xml:lang="en">Palermo M., Quinkler M., Stewart P. M. revisão Apparent Mineralocorticoid Excess Syndrome: An Overview. 2004.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Papizh S. V., Prikhodina L. S. Apparent mineralocorticoid excess syndrome: difficulties of diagnostics and treatment. Review and case report // Nephrology and Dialysis. 2018. № 4 (19). C. 455–465.</mixed-citation><mixed-citation xml:lang="en">Papizh S. V., Prikhodina L. S. Apparent mineralocorticoid excess syndrome: difficulties of diagnostics and treatment. Review and case report // Nephrology and Dialysis. 2018. № 4 (19). C. 455–465.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Tinawi M. Hypokalemia: A Practical Approach to Diagnosis and Treatment // Archives of Clinical and Biomedical Research. 2020. № 02 (04).</mixed-citation><mixed-citation xml:lang="en">Tinawi M. Hypokalemia: A Practical Approach to Diagnosis and Treatment // Archives of Clinical and Biomedical Research. 2020. № 02 (04).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Tapia-Castillo A. [и др.]. Novel metabolomic profile of subjects with non-classic apparent mineralocorticoid excess // Scientific Reports. 2021. № 1 (11).</mixed-citation><mixed-citation xml:lang="en">Tapia-Castillo A. [и др.]. Novel metabolomic profile of subjects with non-classic apparent mineralocorticoid excess // Scientific Reports. 2021. № 1 (11).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Fan P. [и др.]. Apparent mineralocorticoid excess caused by novel compound heterozygous mutations in HSD11B2 and characterized by early-onset hypertension and hypokalemia // Endocrine. 2020. № 3 (70). C. 607–615.</mixed-citation><mixed-citation xml:lang="en">Fan P. [и др.]. Apparent mineralocorticoid excess caused by novel compound heterozygous mutations in HSD11B2 and characterized by early-onset hypertension and hypokalemia // Endocrine. 2020. № 3 (70). C. 607–615.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Carvaja C. A. [и др.]. Classic and nonclassic apparent mineralocorticoid excess syndrome // Journal of Clinical Endocrinology and Metabolism. 2020. Т. 105. № 4. C. E924–E936.</mixed-citation><mixed-citation xml:lang="en">Carvaja C. A. [и др.]. Classic and nonclassic apparent mineralocorticoid excess syndrome // Journal of Clinical Endocrinology and Metabolism. 2020. Т. 105. № 4. C. E924–E936.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Леонова М. В. [и др.]. Эволюция антагонистов минералокортикоидных рецепторов: эплеренон и спиронолактон // Consilium Medicum. 2017. № 10 (19). C. 60-65.</mixed-citation><mixed-citation xml:lang="en">Леонова М. В. [и др.]. Эволюция антагонистов минералокортикоидных рецепторов: эплеренон и спиронолактон // Consilium Medicum. 2017. № 10 (19). C. 60-65.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Папиж С. В., Приходина Л. С. Синдром мнимого избытка минералокортикоидов: трудности диагностики и лечения. Литературный обзор и клиническое наблюдение. Нефрология и диализ. 2017. 19(4):455-465. doi: 10.28996/1680-4422-2017-4-455-465.</mixed-citation><mixed-citation xml:lang="en">Папиж С. В., Приходина Л. С. Синдром мнимого избытка минералокортикоидов: трудности диагностики и лечения. Литературный обзор и клиническое наблюдение. Нефрология и диализ. 2017. 19(4):455-465. doi: 10.28996/1680-4422-2017-4-455-465.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Verma S, Dabadghao P, Moirangthem A. Apparent Mineralocorticoid Excess – A Rare Cause of Endo crine Hypertension. Indian Pediatr Case Rep 2022;2:36-9.</mixed-citation><mixed-citation xml:lang="en">Verma S, Dabadghao P, Moirangthem A. Apparent Mineralocorticoid Excess – A Rare Cause of Endo crine Hypertension. Indian Pediatr Case Rep 2022;2:36-9.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
